Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06267365 · ClinicalTrials.gov registry record
Predictive Biomarker for Endoscopic Therapy in Chronic Pancreatitis
A clinical trial of Chronic Pancreatitis, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT06267365: Recruiting study of Chronic Pancreatitis, sponsored by NYU Langone Health.
NCT06267365 is a study of Chronic Pancreatitis that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 100 participants, below the 687-participant average among 42 other Chronic Pancreatitis trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06267365, a study of Chronic Pancreatitis, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an observational prospective study to develop predictive biomarkers for pain response in participants with chronic pancreatitis scheduled for endoscopic therapy. Participants will undergo baseline assessments including electroencephalography (EEG), quantitative sensory testing (QST), and psychosocial questionnaires. Response to endoscopic therapy will be assessed at approximately 3, 6, 12 and 18 months post-procedure using questionnaires.
Primary Outcome
BPI is a 9-item assessment of pain. Each item is rated on a Likert scale from 0 (No Pain) to 10 (Pain as bad as you can imagine). The total score is the sum of responses and ranges from 0-90; higher scores indicate greater pain.
Conditions Studied
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-11-27 |
| Est. Completion | 2028-06-01 |
What NCT06267365 shows while recruiting
NCT06267365 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 687-participant average among 42 other Chronic Pancreatitis trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Chronic Pancreatitis appearing as the primary indexed condition, and to 0 interventions.
NCT06267365 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06267365 about?
NCT06267365 is a clinical study titled "Predictive Biomarker for Endoscopic Therapy in Chronic Pancreatitis". This is an observational prospective study to develop predictive biomarkers for pain response in participants with chronic pancreatitis scheduled for endoscopic therapy. Participants will undergo baseline assessments including electroencephalography (EEG), quantitative sensory testing (QST), and psy...
What is the current status of trial NCT06267365?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2023-11-27. Estimated completion is 2028-06-01.
What conditions does trial NCT06267365 study?
This clinical trial studies the following conditions: Chronic Pancreatitis.
Who is sponsoring clinical trial NCT06267365?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06267365 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pancreatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06267365's enrollment target sits among peer trials
100 13th of 42 higher than 27 of 42 other Chronic Pancreatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Pancreatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
-
Analysis of Graft Function Following Autologous Islet Transplantation
RECRUITING
-
A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis
RECRUITING · Early Phase 1
-
Scrambler Therapy in Chronic Pancreatitis
RECRUITING · NA
-
Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
RECRUITING
-
Pancreas Registry and High Risk Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI